2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society.

[1]  L. Eckardt,et al.  Clinical experience regarding safety and diagnostic value of cardiovascular magnetic resonance in patients with a subcutaneous implanted cardioverter/defibrillator (S-ICD) at 1.5 T , 2020, Journal of Cardiovascular Magnetic Resonance.

[2]  R. Luechinger,et al.  Magnetic resonance imaging of patients with epicardial leads: in vitro evaluation of temperature changes at the lead tip , 2019, Journal of Interventional Cardiac Electrophysiology.

[3]  M. Doyle,et al.  Integrated use of cardiac MRI and the CardioMEMS™ HF system in PAH: the utility of coincident pressure and volume in RV failure-the NHLBI-VITA trial. , 2019, Cardiovascular diagnosis and therapy.

[4]  N. Schieda,et al.  Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists , 2019, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[5]  C. Steinwender,et al.  Monocenter Investigation Micra® MRI study (MIMICRY): feasibility study of the magnetic resonance imaging compatibility of a leadless pacemaker system , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  H. Schild,et al.  Safety and Feasibility of Magnetic Resonance Imaging of the Brain at 1.5 Tesla in Patients with Temporary Transmyocardial Pacing Leads , 2017, The Thoracic and Cardiovascular Surgeon.

[7]  Jason R. Shewchuk,et al.  Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists , 2018, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[8]  S. Matthew,et al.  Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals , 2018, European Radiology.

[9]  R. Lenkinski,et al.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. , 2018, Radiology.

[10]  Yijian Huang,et al.  Magnetic resonance imaging safety in nonconditional pacemaker and defibrillator recipients: A meta-analysis and systematic review. , 2018, Heart rhythm.

[11]  J. Finn,et al.  Cardiac magnetic resonance imaging using wideband sequences in patients with nonconditional cardiac implanted electronic devices. , 2017, Heart rhythm.

[12]  J. Felmlee,et al.  Safety of magnetic resonance imaging in patients with legacy pacemakers and defibrillators and abandoned leads. , 2017, Heart rhythm.

[13]  M. Prince,et al.  Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis. , 2017, Radiology.

[14]  Stefan L. Zimmerman,et al.  Safety of Magnetic Resonance Imaging in Patients with Cardiac Devices , 2017, The New England journal of medicine.

[15]  C. Ching,et al.  Clinical safety and performance of a MRI conditional pacing system in patients undergoing cardiac MRI , 2017, Pacing and clinical electrophysiology : PACE.

[16]  Cyprian Olchowy,et al.  The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review , 2017, PloS one.

[17]  A. Dohan,et al.  Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study , 2016, Journal of magnetic resonance imaging : JMRI.

[18]  Jason C. Rubenstein,et al.  Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. , 2017, The New England journal of medicine.

[19]  Craig L. Wiklund,et al.  Safety evaluation of a leadless transcatheter pacemaker for magnetic resonance imaging use. , 2016, Heart rhythm.

[20]  O. Naggara,et al.  Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses , 2016, Investigative radiology.

[21]  P. Mittal,et al.  Safety and Quality of 1.5-T MRI in Patients With Conventional and MRI-Conditional Cardiac Implantable Electronic Devices After Implementation of a Standardized Protocol. , 2016, AJR. American journal of roentgenology.

[22]  W. Haverkamp,et al.  Cardiovascular Magnetic Resonance Imaging in Patients with an Implantable Loop Recorder , 2016, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[23]  M. Gold,et al.  Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment , 2016, Circulation. Cardiovascular imaging.

[24]  Thomas C. Crawford,et al.  Clinical safety of the Iforia implantable cardioverter-defibrillator system in patients subjected to thoracic spine and cardiac 1.5-T magnetic resonance imaging scanning conditions. , 2015, Heart rhythm.

[25]  S. Wolff,et al.  MRI scanning in patients with new and existing CapSureFix Novus 5076 pacemaker leads: randomized trial results. , 2015, Heart rhythm.

[26]  P. Neužil,et al.  Magnetic resonance imaging in patients with a subcutaneous implantable cardioverter-defibrillator , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  M. Tozaki,et al.  A multicenter, randomized, controlled, single‐blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast‐enhanced MRI of the body regions or extremities , 2015, Journal of magnetic resonance imaging : JMRI.

[28]  G. Calcagnini,et al.  Impact of capped and uncapped abandoned leads on the heating of an MR‐conditional pacemaker implant , 2015, Magnetic resonance in medicine.

[29]  A. Verma,et al.  Canadian Heart Rhythm Society and Canadian Association of Radiologists consensus statement on magnetic resonance imaging with cardiac implantable electronic devices. , 2014, The Canadian journal of cardiology.

[30]  J. Felmlee,et al.  Safety and Outcomes of Magnetic Resonance Imaging in Patients with Abandoned Pacemaker and Defibrillator Leads , 2014, Pacing and clinical electrophysiology : PACE.

[31]  Marmar Vaseghi,et al.  Improved late gadolinium enhancement MR imaging for patients with implanted cardiac devices. , 2013, Radiology.

[32]  J. Felmlee,et al.  Magnetic Resonance Imaging in Patients with Recently Implanted Pacemakers , 2013, Pacing and clinical electrophysiology : PACE.

[33]  David L. Hayes,et al.  Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla. , 2013, Heart rhythm.

[34]  H. Halperin,et al.  Quantitative Assessment of Artifacts on Cardiac Magnetic Resonance Imaging of Patients With Pacemakers and Implantable Cardioverter-Defibrillators , 2011, Circulation. Cardiovascular imaging.

[35]  H. Halperin,et al.  A Prospective Evaluation of a Protocol for Magnetic Resonance Imaging of Patients With Implanted Cardiac Devices , 2011, Annals of Internal Medicine.

[36]  M. Endres,et al.  Safety and reliability of the insertable Reveal XT recorder in patients undergoing 3 Tesla brain magnetic resonance imaging. , 2011, Heart rhythm.

[37]  Daniel B Ennis,et al.  Pacemaker lead tip heating in abandoned and pacemaker‐attached leads at 1.5 tesla MRI , 2011, Journal of magnetic resonance imaging : JMRI.

[38]  T. Frenzel,et al.  Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.

[39]  Martin R Prince,et al.  Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.

[40]  L. Shaw,et al.  Removal of gadolinium by peritoneal dialysis. , 2008, Clinical nephrology.

[41]  Ian G. Ross,et al.  Feasibility of Magnetic Resonance Imaging in Patients with an Implantable Loop Recorder , 2008, Pacing and clinical electrophysiology : PACE.

[42]  R. Rodby.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Dialytic Therapies to Prevent NSF Following Gadolinium Exposure in High‐Risk Patients , 2008, Seminars in dialysis.

[43]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[44]  H. Halperin,et al.  Clinical Utility and Safety of a Protocol for Noncardiac and Cardiac Magnetic Resonance Imaging of Patients With Permanent Pacemakers and Implantable-Cardioverter Defibrillators at 1.5 Tesla , 2006, Circulation.

[45]  B. Wilkoff,et al.  Safe Scanning, but Frequent Artifacts Mimicking Bradycardia and Tachycardia During Magnetic Resonance Imaging (MRI) in Patients with an Implantable Loop Recorder (ILR) , 2005, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[46]  Ron Kalin,et al.  Current Clinical Issues for MRI Scanning of Pacemaker and Defibrillator Patients , 2005, Pacing and clinical electrophysiology : PACE.

[47]  Robert Fair,et al.  Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. , 2004, Journal of the American College of Cardiology.